Literature DB >> 12200761

Beta-cell dysfunction in late-onset diabetic subjects carrying homozygous mutation in transcription factors NeuroD1 and Pax4.

Azuma Kanatsuka1, Yoshiharu Tokuyama, Osamu Nozaki, Kana Matsui, Tohru Egashira.   

Abstract

Polymorphisms in beta-cell transcription factor genes, Ala45Thr in the NeuroD1 gene and Arg121Trp in the Pax4 gene, have been reported. To clarify the role of these mutations in the pathogenesis of late-onset diabetes, we examined the insulin secretion and sensitivity in diabetic patients carrying the homozygous mutation in the NeuroD1 gene or Pax4 gene. We screened for the polymorphisms in NeuroD1 and Pax4 genes in 296 late-onset diabetic patients and 177 unrelated control subjects over 60 years of age. Genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) followed by direct sequencing. Acute insulin secretion was evaluated using a 2-compartment model analysis of C-peptide kinetics after intravenous glucose load (CS1). Insulin sensitivity was estimated by the insulin-modified minimal model analysis (Si). Four diabetic patients carried the homozygous mutation (Thr/Thr) in the NeuroD1 gene and 3 patients carried the homozygous mutation (Trp/Trp) in the Pax4 gene, while both homozygous mutations were not detected in the control subjects. In patients A, B, C, and D with homozygous mutations in NeuroD1, CS1 (normal range, 6.8 to 18.5 ng/mL/min) was 0.508, 1.481, 1.223, and 1.584 ng/mL/min, respectively, and Si (normal range, 2.6 to 7.6 x 10(-4)/min/[microU/mL]) was 0.727, 3.31, 3.79, and 0.00 x 10(-4)/min/(microU/mL), respectively. In patients X, Y, and Z with homozygous mutation in Pax4, CS was 0.418, 0.208, and 1.279 ng/mL/min, respectively, and Si was 1.11, 2.88, and 0.00 x 10(-4)/min/(microU/mL), respectively. Since acute insulin secretion in response to glucose was markedly impaired and insulin resistance was varied in the patients carrying the homozygous mutations in the NeuroD1 and Pax4 genes, the mutations are ones of the factors involved in the beta-cell dysfunction and do not relate to the insulin resistance. These homozygous mutations appear to play a part in the pathogenesis of beta-cell defect in about 2.5% of Japanese patients with late-onset diabetes. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12200761     DOI: 10.1053/meta.2002.34707

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  14 in total

1.  Beta cell regeneration meets autoimmunity: PAX4 variants in type 1 diabetes.

Authors:  M Tiedge
Journal:  Diabetologia       Date:  2005-05       Impact factor: 10.122

2.  To: Biason-Lauber A, Boehm B, Lang-Muritano M et al. (2005) association of childhood type 1 diabetes mellitus with a variant of PAX4: possible link to beta cell regenerative capacity. Diabetologia 48:900-905.

Authors:  T Gylvin; R Bergholdt; J Nerup; F Pociot
Journal:  Diabetologia       Date:  2005-08-13       Impact factor: 10.122

3.  Ala45Thr polymorphism of the NEUROD1 gene and diabetes susceptibility: a meta-analysis.

Authors:  Fotini K Kavvoura; John P A Ioannidis
Journal:  Hum Genet       Date:  2004-12-11       Impact factor: 4.132

Review 4.  Translational implications of the β-cell epigenome in diabetes mellitus.

Authors:  Justin S Johnson; Carmella Evans-Molina
Journal:  Transl Res       Date:  2014-03-12       Impact factor: 7.012

5.  Ala45Thr variation in neuroD1 gene is associated with early-onset type 2 diabetes with or without diabetic pedigree in Chinese.

Authors:  Limei Liu; Weiping Jia; Taishan Zheng; Ming Li; Huijuan Lu; Kunsan Xiang
Journal:  Mol Cell Biochem       Date:  2006-06-14       Impact factor: 3.396

6.  NeuroD1 A45T and PAX4 R121W polymorphisms are associated with plasma glucose level of repaglinide monotherapy in Chinese patients with type 2 diabetes.

Authors:  Zhi-Cheng Gong; Qiong Huang; Xing-Ping Dai; Guang-Hua Lei; Hong-Bin Lu; Ji-Ye Yin; Xiao-Jing Xu; Jian Qu; Qi Pei; Min Dong; Bo-Ting Zhou; Jie Shen; Gan Zhou; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

Review 7.  Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.

Authors:  Gaia Chiara Mannino; Giorgio Sesti
Journal:  Mol Diagn Ther       Date:  2012-10       Impact factor: 4.074

8.  No association of the IRS1 and PAX4 genes with type I diabetes.

Authors:  R Bergholdt; C Brorsson; B Boehm; G Morahan; F Pociot
Journal:  Genes Immun       Date:  2009-12       Impact factor: 2.676

9.  Evaluation of variant A45T in NEUROD1/BETA2 for its association with type 2 diabetes mellitus.

Authors:  Xueyao Han; Jianzhong Xiao; Qian Ren; Yong Tang; Wenying Yang; Linong Ji
Journal:  Endocrine       Date:  2012-12-01       Impact factor: 3.633

10.  MMARGE: Motif Mutation Analysis for Regulatory Genomic Elements.

Authors:  Verena M Link; Casey E Romanoski; Dirk Metzler; Christopher K Glass
Journal:  Nucleic Acids Res       Date:  2018-08-21       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.